Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: Comparison with phenytoin

Epilepsy Research

Volumn 30, Issue 1, 1998, Pages 69-76

  Löscher, Wolfgang ^a   Reissmüller, Elke ^a   Ebert, Ulrich ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

ACC 9653; Afterdischarge threshold; Bioavailability; Kindling; Limbic seizure

Indexed keywords

FOSPHENYTOIN SODIUM; PHENYTOIN; PRODRUG;

AFTERDISCHARGE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TRANSFORMATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; KINDLING; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD;

AMYGDALA; ANIMALS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY, COMPLEX PARTIAL; FEMALE; KINDLING, NEUROLOGIC; PHENYTOIN; PRODRUGS; RATS; RATS, WISTAR;

EID: 0042929063     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00098-3     Document Type: Article

References (35)

1. Albertson T.E., Peterson S.L., Stark L.G. Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats. Neuropharmacology. 19:1980;643-652.
2. Albright P.S., Burnham W.M. Development of a new pharmacological seizure model: Effects of anticonvulsants on cortical- and amygdala-kindled seizures in the rat. Epilepsia. 21:1980;681-689.
3. Browne T.R., Davoudi H., Donn K.H., Dougherty C.L., Dukes G.E., Evans B., Evans J.E., Jamerson B., Kres J., McEntegart C.M. Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia. 30(Suppl. 2):1989;S27-S32.
4. Callahan D.A., Schwark W.S. Pharmacological modification of amygdaloid-kindled seizures. Neuropharmacology. 19:1980;1131-1136.
5. Cranford R.E., Leppik I.E., Patrick B., Anderson C.B., Kostick B. Intravenous phenytoin in acute treatment of seizures. Neurology. 28:1978;874-880.
6. Ebert U., Rundfeldt C., Löscher W. Sex differences in the anticonvulsant efficacy of phenytoin in amygdala-kindled rats. Brain Res. 638:1994;45-52.
7. Ebert U., Rundfeldt C., Löscher W. Development and pharmacological suppression of secondary afterdischarges in the hippocampus of amygdala-kindled rats. Eur. J. Neurosci. 7:1995;732-741.
8. Ebert U., Cramer S., Löscher W. Phenytoin's effect on the spread of seizure activity in the amygdala kindling model. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;341-347.
9. Ehle A.L. Effects of phenytoin on amygdaloid kindled seizures in the rat. Electroencephalogr. Clin. Neurophysiol. 48:1980;102-105.
10. Kutt H., Louis S., McDowell F. Intravenous diphenylhydantoin in experimental seizures. Arch. Neurol. 18:1968;465-477.
11. Leppik I.E., Boucher R., Wilder B.J., Murthy V.S., Rask C.A., Watridge C., Graves N.M., Rangel R.J., Turlapaty P. Phenytoin prodrug: preclinical and clinical studies. Epilepsia. 30(Suppl. 2):1989;S22-S26.
12. Louis S., Kutt H., McDowell F. The cardiovasculatory changes caused by intravenous dilantin and its solvent. Am. Heart J. 74:1967;523-529.
13. Löscher W. Animal models of intractable epilepsy. Prog. Neurobiol. 53:1997;239-258.
14. Löscher W., Schmidt D. Which animal models should be used in the search of new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
15. Löscher W., Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37489 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J. Pharmacol. Exp. Ther. 256:1991;432-440.
16. Löscher W., Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. J. Pharmacol. Exp. Ther. 258:1991;483-489.
17. Löscher W., Jäckel R., Czuczwar S.J. Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp. Neurol. 93:1986;211-226.
18. Löscher W., Rundfeldt C., Hönack D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res. 9:1993;11-18.
19. Lothman E.W., Williamson J.M., Van Landingham K.E. Intraperitoneal phenytoin suppresses kindled responses: effects on motor and electrographic seizures. Epilepsy Res. 9:1991;11-18.
20. Mace J.A., Burnham W.M. The effect of repeated seizures on anticonvulsant drug response in the kindling model. Electroencephalogr. Clin. Neurophysiol. 67:1987;171-175.
21. McNamara J.O. Kindling: an animal model of complex partial epilepsy. Ann. Neurol. 16:1984;S72-76.
22. McNamara J.O., Rigsbee L.C., Butler L.S., Shin C. Intravenous phenytoin is an effective anticonvulsant in the kindling model. Ann. Neurol. 26:1989;675-678.
23. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, Sydney, 1986.
24. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32:1972;281-294.
25. Racine R., Livingston K., Joaquin A. Effects of procaine hydrochloride, diazepam, and diphenylhydantoin on seizure development in cortical and subcortical structures in rats. Electroencephalogr. Clin. Neurophysiol. 38:1975;355-365.
26. Renfrey G., Schlinger H., Jakubow J., Poling A. Effects of phenytoin and phenobarbital on schedule-controlled responding and seizure activity in the amygdala-kindled rat. J. Pharmacol. Exp. Ther. 248:1989;967-973.
27. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
28. Rundfeldt C., Löscher W. Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J. Pharmacol. Exp. Ther. 266:1993;216-223.
29. Rundfeldt C., Hönack D., Löscher W. Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology. 29:1990;845-851.
30. Schmutz M., Klebs K., Baltzer V. Inhibition or enhancement of kindling evolution by antiepileptics. J. Neural. Transm. 72:1988;245-257.
31. Smith R.D., Brown B.S., Maher R.W., Matier W.L. Pharmacology of ACC-9653 (phenytoin prodrug). Epilepsia. 30(Suppl. 2):1989;S15-S21.
32. Voits M., Frey H.H. Stimulation-dependent effect of antiepileptic drugs in amygdala kindled rats on both seizure score and duration of afterdischarges. Pharmacol. Toxicol. 75:1994;54-61.
33. Wallis W., Kutt H., McDowell F. Intravenous phenytoin in treatment of acute repetitive seizures. Neurology. 18:1968;513-525.
34. Walton N.Y., Treiman D.M. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. Epilepsy Res. 5:1990;165-168.
35. Wilder B.K., Ramsay R.E., Willmore J., Feussner G.F., Perchalski R.J., Shumate J.B. Efficacy of intravenous phenytoin in the treatment of status epilepticus: kinetics and central nervous system penetration. Ann. Neurol. 1:1977;511-518.